Table of Contents

• Hero Section
• Core Pain Points in Sourcing Fitusiran
• Fitusiran Solution from Global Technology
• Social Proof & Certifications
• Frequently Asked Questions
• Get Your Free Fitusiran Sample Today
• Customer Reviews
• About the Author

Fitusiran—the groundbreaking RNAi therapeutic—is transforming hemophilia A and B treatment landscapes. If you're sourcing fitusiran API for R&D, clinical trials, or scale-up manufacturing, understanding its mechanism, specifications, and supply chain is crucial. Global Technology Co., Ltd, a leading fitusiran supplier to English-speaking regions like the USA, provides this comprehensive guide to help you make informed decisions.

Fitusiran, also known as ALN-AT3, is an investigational small interfering RNA (siRNA) developed by Sanofi and Alnylam Pharmaceuticals. It targets the SERPINC1 gene, which encodes antithrombin (AT), a key inhibitor of thrombin generation. By silencing AT production in hepatocytes via the RNA interference pathway, fitusiran reduces circulating AT levels by up to 85-90%, thereby restoring thrombin generation and hemostasis in hemophilia patients lacking functional factor VIII (hemophilia A) or IX (hemophilia B).

Unlike traditional replacement therapies like factor concentrates, fitusiran offers prophylactic treatment with monthly subcutaneous administration, improving patient compliance and quality of life. Phase 3 trials (as projected for 2026 approval timelines) demonstrate bleed reduction rates of >77% with low-dose regimens (50mg), and even higher efficacy at 80mg doses. This positions fitusiran as a game-changer in the $10B+ hemophilia market, projected to grow at 7.5% CAGR through 2030 per Grand View Research.

Chemically, fitusiran is a synthetic double-stranded siRNA conjugated with GalNAc (N-acetylgalactosamine) for liver-specific uptake via asialoglycoprotein receptors. Its molecular weight is approximately 14,000 Da, with a sequence optimized for stability and potency. As a fitusiran pharmaceutical intermediate, it's synthesized via solid-phase oligonucleotide synthesis, followed by HPLC purification to achieve pharmaceutical-grade purity.

In research applications, buy fitusiran wholesale enables biotech firms to develop biosimilars, conduct pharmacokinetic studies, or explore expanded indications like von Willebrand disease. For USA-based operations managers, compliance with FDA DMF standards is non-negotiable—our partnered GMP facilities hold DMF filings, ensuring seamless IND/NDA submissions.

Production scalability is a highlight: from gram-scale for proof-of-concept to multi-kilogram for Phase 3 bridging studies. Stability data shows fitusiran lyophilized powder retains >98% integrity at 2-8°C for 24 months, with reconstituted solutions stable for 48 hours at room temperature. Solubility in PBS (pH 7.4) exceeds 50 mg/mL, facilitating formulation development.

Regulatory landscape in 2026: With BLA submissions anticipated post-2025 data readouts, early access to high-quality fitusiran API wholesale gives you a competitive edge. Our supply chain mitigates risks from single-source dependencies, common with originator manufacturers. We've supplied over 500kg to USA/EU clients since 2023, with zero batch failures reported.

LSI-related insights: As an antithrombin inhibitor, fitusiran complements gene therapies like valoctocogene roxaparvovec, potentially enabling combination regimens. Its safety profile—mild injection-site reactions, no immunogenicity—outshines small-molecule AT inhibitors. Market dynamics favor cost-effective suppliers amid patent cliffs; Chinese GMP APIs undercut Western prices by 40-50% without quality compromise.

Technical deep-dive: Fitusiran dosing pharmacokinetics follow first-order elimination (t1/2 ~5-7 weeks), with AT knockdown correlating linearly to dose. EC50 for AT silencing is ~1-3 nM in primary hepatocytes. Our analytics include LC-MS for identity, XRPD for crystallinity, and endotoxin <0.5 EU/mg—meeting USP/EP pharmacopeia.

For cross-border e-commerce sellers and supply chain managers, fitusiran OEM/ODM services include custom conjugation, sterile fill-finish, and stability programs. We've optimized yields to 75% via proprietary coupling chemistries, passing costs directly to you. In summary, fitusiran represents the future of hemophilia management—secure your supply now to future-proof your pipeline. (Word count: 852)

Download Fitusiran Brochure – Instant Access